Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,947 public trials 2,015 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, Not Recruiting

Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

NCT03712202

Conditions
Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Lymphocyte-Depleted Classic HL, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, +20 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • City of Hope Medical Center Duarte, California, United States
  • University of California San Diego San Diego, California, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
View all 17 locations
View Trial Details
Active, Not Recruiting

Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse

NCT04475731

Conditions
Acute Lymphoblastic Leukemia, in Relapse, Hematologic Diseases, Hemic and Lymphatic Diseases, +10 more
Locations
  • Aou Ospedali Riuniti "Umberto I - G.M. Lancisi - G. Salesi"- Ancona - Sod Clinica Ematologica Ancona, Italy
  • Area Vasta N. 5 Ascoli Piceno - S. Benedetto Del Tronto, Presidio Ospedaliero Av5 Osp. Gen. Prov.Le "C.G.Mazzoni" - Uoc Ematologia Ascoli Piceno, Italy
  • Ao Di Rilievo Nazionale E Di Alta Specialità "San Giuseppe Moscati" - Avellino - Uoc Ematologia Con Unità Di Trapianto Avellino, Italy
  • Aou Consorziale Policlinico - Bari - Uo Ematologia Con Trapianto Bari, Italy
View all 22 locations
View Trial Details
Active, Not Recruiting

Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL

NCT04624958

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Guangdong General Hospital Guangzhou, Guangdong, China
  • Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
  • The First Affiliated Hospital of Guangdong Pharmaceutical University Guangzhou, Guangdong, China
View Trial Details
Active, Not Recruiting

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

NCT05202782

Conditions
Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Hemic and Lymphatic Diseases, +27 more
Locations
  • Northwestern University Chicago, Illinois, United States
  • Medical College of Wisconsin Milwaukee, Wisconsin, United States
View Trial Details
Active, Not Recruiting

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

NCT05406401

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations
  • BC Cancer Victoria-Clinical Trials Unit ( Site 0105) Victoria, British Columbia, Canada
  • William Osler Health System ( Site 0106) Toronto, Ontario, Canada
  • Hopital du Sacre-Coeur de Montreal ( Site 0108) Montreal, Quebec, Canada
  • Hadassah Medical Center ( Site 0401) Jerusalem, Israel
View all 22 locations
View Trial Details
Active, Not Recruiting

Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy

NCT02889523

Conditions
DLBCL, Follicular Lymphoma, Hemic and Lymphatic Diseases, +9 more
Locations
  • Institut Jules Bordet Brussels, Belgium
  • CHU de Liege Liège, Belgium
  • CHRU Mont Godinne Yvoir, Belgium
  • Centre Hospitalier Victor Dupouy Argenteuil, France
View all 31 locations
View Trial Details
Active, Not Recruiting

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

NCT04756401

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Hackensack University Medical Center Hackensack, New Jersey, United States
  • State University of New York Upstate Medical University Syracuse, New York, United States
  • UNC Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Chapel Hill, North Carolina, United States
  • Carolinas Medical Center/Levine Cancer Institute Charlotte, North Carolina, United States
View Trial Details

Related conditions